Extending the Definition of the GyrB Quinolone Resistance-Determining Region in Mycobacterium tuberculosis DNA Gyrase for Assessing Fluoroquinolone Resistance in M. tuberculosis
- 1 April 2012
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (4), 1990-1996
- https://doi.org/10.1128/aac.06272-11
Abstract
Fluoroquinolone (FQ) resistance is emerging in Mycobacterium tuberculosis . The main mechanism of FQ resistance is amino acid substitution within the quinolone resistance-determining region (QRDR) of the GyrA subunit of DNA gyrase, the sole FQ target in M. tuberculosis . However, substitutions in GyrB whose implication in FQ resistance is unknown are increasingly being reported. The present study clarified the role of four GyrB substitutions identified in M. tuberculosis clinical strains, two located in the QRDR (D500A and N538T) and two outside the QRDR (T539P and E540V), in FQ resistance. We measured FQ MICs and also DNA gyrase inhibition by FQs in order to unequivocally clarify the role of these mutations in FQ resistance. Wild-type GyrA, wild-type GyrB, and mutant GyrB subunits produced from engineered gyrB alleles by mutagenesis were overexpressed in Escherichia coli , purified to homogeneity, and used to reconstitute highly active gyrase complexes. MICs and DNA gyrase inhibition were determined for moxifloxacin, gatifloxacin, ofloxacin, levofloxacin, and enoxacin. All these substitutions are clearly implicated in FQ resistance, underlining the presence of a hot spot region housing most of the GyrB substitutions implicated in FQ resistance (residues NTE, 538 to 540). These findings help us to refine the definition of GyrB QRDR, which is extended to positions 500 to 540.Keywords
This publication has 30 references indexed in Scilit:
- DNA Gyrase Inhibition Assays Are Necessary To Demonstrate Fluoroquinolone Resistance Secondary to gyrB Mutations in Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2011
- Impact of the E540V Amino Acid Substitution in GyrB of Mycobacterium tuberculosis on Quinolone ResistanceAntimicrobial Agents and Chemotherapy, 2011
- Performance Assessment of the GenoType MTBDR sl Test and DNA Sequencing for Detection of Second-Line and Ethambutol Drug Resistance among Patients Infected with Multidrug-Resistant Mycobacterium tuberculosisJournal of Clinical Microbiology, 2011
- Should Moxifloxacin Be Used for the Treatment of Extensively Drug-Resistant Tuberculosis? An Answer from a Murine ModelAntimicrobial Agents and Chemotherapy, 2010
- Evaluation of the MTBDRsl Test for Detection of Second-Line-Drug Resistance in Mycobacterium tuberculosisJournal of Clinical Microbiology, 2010
- Beijing Genotype of Mycobacterium tuberculosis Is Significantly Associated with High-Level Fluoroquinolone Resistance in VietnamAntimicrobial Agents and Chemotherapy, 2009
- Fluoroquinolone Resistance in Mycobacterium tuberculosis and Mutations in gyrA and gyrBAntimicrobial Agents and Chemotherapy, 2009
- Sequence Analyses of Just Four Genes To Detect Extensively Drug-Resistant Mycobacterium tuberculosis Strains in Multidrug-Resistant Tuberculosis Patients Undergoing TreatmentAntimicrobial Agents and Chemotherapy, 2009
- Molecular Characterization of Ofloxacin-Resistant Mycobacterium tuberculosis Strains from RussiaAntimicrobial Agents and Chemotherapy, 2008
- Functional Analysis of DNA Gyrase Mutant Enzymes Carrying Mutations at Position 88 in the A Subunit Found in Clinical Strains of Mycobacterium tuberculosis Resistant to FluoroquinolonesAntimicrobial Agents and Chemotherapy, 2006